From the Journals

Distinguish neurogenic from nonneurogenic orthostatic hypotension


 

FROM ANNALS OF NEUROLOGY

In order to distinguish neurogenic from nonneurogenic causes of orthostatic hypotension, looking at the change in heart rate (cHR) in relation to the change in systolic blood pressure (cSBP) may be superior to looking at heart rate alone.

A cHR/cSBP ratio of 0.492 beats per minute (bpm)/mm Hg had the best sensitivity and specificity to distinguish neurogenic from nonneurogenic causes, according to results of a prospective study published in Annals of Neurology.

Dr. Lucy Norcliffe-Kaufmann, director of the Dysautonomia Center at NYU Langone Medical Center, New York

Dr. Lucy Norcliffe-Kaufmann

Patients with a ratio less than 0.5 might need additional screening for primary or secondary causes of autonomic failure, according to researcher Lucy Norcliffe-Kaufmann, PhD, associate director of the Dysautonomia Center at NYU Langone Medical Center, New York.

“If you just look at the heart rate increase alone, of course it is blunted, but it doesn’t really give you the bigger picture that you get when you look at the heart rate in relation to the blood pressure fall,” Dr. Norcliffe-Kaufmann said in an interview.

Neurogenic orthostatic hypotension, which indicates an underlying pathology affecting autonomic neurons, has a much worse prognosis than does nonneurogenic orthostatic hypotension, according to Dr. Norcliffe-Kaufmann and her colleagues, who published the results on behalf of the Autonomic Disorders Consortium.

One key difference between the two groups, they added, is that patients with neurogenic orthostatic hypotension typically have little or no heart rate (HR) increase in the upright position, while patients with nonneurogenic orthostatic hypotension may have marked tachycardia.

Despite the importance of orthostatic HR changes in differential diagnosis, however, there has been no systematic evaluation of HR ranges that may be diagnostic, and proposed ranges have been based on expert clinical experience rather than clinical data, they said.

Pages

Recommended Reading

Extended-release amantadine approved for treatment of dyskinesia in Parkinson’s
MDedge Family Medicine
Austedo approved for treatment of tardive dyskinesia
MDedge Family Medicine
Exenatide improved motor function in Parkinson’s patients with off-medication symptoms
MDedge Family Medicine
Poor smell predicts 6-year risk of Parkinson’s
MDedge Family Medicine
Slow-wave sleep linked to Parkinson’s disease cognition
MDedge Family Medicine
Driving ability of Parkinson’s patients can decline quickly
MDedge Family Medicine
High-intensity treadmill workouts preserved motor function in early-stage Parkinson’s
MDedge Family Medicine
Gene silencer reduces mutant huntingtin protein in early-stage Huntington’s patients
MDedge Family Medicine
FDA cites manufacturer of autologous stem cells for regulatory, manufacturing missteps
MDedge Family Medicine
Mutations on LRRK2 gene modify risks for both Crohn’s and Parkinson’s
MDedge Family Medicine